<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="2">35501931</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2051-5960</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>Acta neuropathologica communications</Title>
          <ISOAbbreviation>Acta Neuropathol Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Acute axon damage and demyelination are mitigated by 4-aminopyridine (4-AP) therapy after experimental traumatic brain injury.</ArticleTitle>
        <Pagination>
          <StartPage>67</StartPage>
          <MedlinePgn>67</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">67</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s40478-022-01366-z</ELocationID>
        <Abstract>
          <AbstractText>Damage to long axons in white matter tracts is a major pathology in closed head traumatic brain injury (TBI). Acute TBI treatments are needed that protect against axon damage and promote recovery of axon function to prevent long term symptoms and neurodegeneration. Our prior characterization of axon damage and demyelination after TBI led us to examine repurposing of 4-aminopyridine (4-AP), an FDA-approved inhibitor of voltage-gated potassium (Kv) channels. 4-AP is currently indicated to provide symptomatic relief for patients with chronic stage multiple sclerosis, which involves axon damage and demyelination. We tested clinically relevant dosage of 4-AP as an acute treatment for experimental TBI and found multiple benefits in corpus callosum axons. This randomized, controlled pre-clinical study focused on the first week after TBI, when axons are particularly vulnerable. 4-AP treatment initiated one day post-injury dramatically reduced axon damage detected by intra-axonal fluorescence accumulations in Thy1-YFP mice of both sexes. Detailed electron microscopy in C57BL/6 mice showed that 4-AP reduced pathological features of mitochondrial swelling, cytoskeletal disruption, and demyelination at 7 days post-injury. Furthermore, 4-AP improved the molecular organization of axon nodal regions by restoring disrupted paranode domains and reducing Kv1.2 channel dispersion. 4-AP treatment did not resolve deficits in action potential conduction across the corpus callosum, based on ex vivo electrophysiological recordings at 7 days post-TBI. Thus, this first study of 4-AP effects on axon damage in the acute period demonstrates a significant decrease in multiple pathological hallmarks of axon damage after experimental TBI.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Radomski</LastName>
            <ForeName>Kryslaine L</ForeName>
            <Initials>KL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD, 20814, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Neuroscience and Regenerative Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD, 20814, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zi</LastName>
            <ForeName>Xiaomei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD, 20814, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Neuroscience and Regenerative Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD, 20814, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lischka</LastName>
            <ForeName>Fritz W</ForeName>
            <Initials>FW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD, 20814, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Biomedical Instrumentation Center, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD, 20814, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Noble</LastName>
            <ForeName>Mark D</ForeName>
            <Initials>MD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Genetics, School of Medicine and Dentistry, University of Rochester, 601 Elmwood Ave, Box 633, Rochester, NY, 14642, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Galdzicki</LastName>
            <ForeName>Zygmunt</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD, 20814, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Neuroscience and Regenerative Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD, 20814, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Armstrong</LastName>
            <ForeName>Regina C</ForeName>
            <Initials>RC</Initials>
            <Identifier Source="ORCID">0000-0001-7296-6750</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD, 20814, USA. regina.armstrong@usuhs.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Neuroscience and Regenerative Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD, 20814, USA. regina.armstrong@usuhs.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Acta Neuropathol Commun</MedlineTA>
        <NlmUniqueID>101610673</NlmUniqueID>
        <ISSNLinking>2051-5960</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>BH3B64OKL9</RegistryNumber>
          <NameOfSubstance UI="D015761">4-Aminopyridine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015761" MajorTopicYN="N">4-Aminopyridine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000070642" MajorTopicYN="Y">Brain Injuries, Traumatic</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">4-aminopyridine</Keyword>
        <Keyword MajorTopicYN="Y">Demyelination</Keyword>
        <Keyword MajorTopicYN="Y">Electrophysiology</Keyword>
        <Keyword MajorTopicYN="Y">Kv1.2</Keyword>
        <Keyword MajorTopicYN="Y">Traumatic brain injury</Keyword>
        <Keyword MajorTopicYN="Y">White matter</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no competing financial interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>0</Hour>
          <Minute>17</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35501931</ArticleId>
        <ArticleId IdType="pmc">PMC9059462</ArticleId>
        <ArticleId IdType="doi">10.1186/s40478-022-01366-z</ArticleId>
        <ArticleId IdType="pii">10.1186/s40478-022-01366-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Agren R, Nilsson J, Arhem P. Closed and open state dependent block of potassium channels cause opposing effects on excitability - a computational approach. Sci Rep. 2019;9:8175. doi: 10.1038/s41598-019-44564-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-44564-x</ArticleId>
            <ArticleId IdType="pmc">PMC6546692</ArticleId>
            <ArticleId IdType="pubmed">31160624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andravizou A, Dardiotis E, Artemiadis A, Sokratous M, Siokas V, Tsouris Z, Aloizou AM, Nikolaidis I, Bakirtzis C, Tsivgoulis G, et al.  Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options. Auto Immun Highlights. 2019;10:7. doi: 10.1186/s13317-019-0117-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13317-019-0117-5</ArticleId>
            <ArticleId IdType="pmc">PMC7065319</ArticleId>
            <ArticleId IdType="pubmed">32257063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balan IS, Saladino AJ, Aarabi B, Castellani RJ, Wade C, Stein DM, Eisenberg HM, Chen HH, Fiskum G. Cellular alterations in human traumatic brain injury: changes in mitochondrial morphology reflect regional levels of injury severity. J Neurotrauma. 2013;30:367–381. doi: 10.1089/neu.2012.2339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/neu.2012.2339</ArticleId>
            <ArticleId IdType="pmc">PMC3589878</ArticleId>
            <ArticleId IdType="pubmed">23131111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bei F, Lee HHC, Liu X, Gunner G, Jin H, Ma L, Wang C, Hou L, Hensch TK, Frank E, et al.  Restoration of visual function by enhancing conduction in regenerated axons. Cell. 2016;164:219–232. doi: 10.1016/j.cell.2015.11.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2015.11.036</ArticleId>
            <ArticleId IdType="pmc">PMC4863988</ArticleId>
            <ArticleId IdType="pubmed">26771493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boscia F, Elkjaer ML, Illes Z, Kukley M. Altered expression of ion channels in white matter lesions of progressive multiple sclerosis: what do we know about their function? Front Cell Neurosci. 2021;15:685703. doi: 10.3389/fncel.2021.685703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fncel.2021.685703</ArticleId>
            <ArticleId IdType="pmc">PMC8282214</ArticleId>
            <ArticleId IdType="pubmed">34276310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bradshaw DV, Jr, Kim Y, Fu A, Marion CM, Radomski KL, McCabe JT, Armstrong RC. Repetitive blast exposure produces white matter axon damage without subsequent myelin remodeling: in vivo analysis of brain injury using fluorescent reporter mice. Neurotrauma Rep. 2021;2:180–192. doi: 10.1089/neur.2020.0058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/neur.2020.0058</ArticleId>
            <ArticleId IdType="pmc">PMC8127063</ArticleId>
            <ArticleId IdType="pubmed">34013219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bradshaw DV, Jr, Knutsen AK, Korotcov A, Sullivan GM, Radomski KL, Dardzinski BJ, Zi X, McDaniel DP, Armstrong RC. Genetic inactivation of SARM1 axon degeneration pathway improves outcome trajectory after experimental traumatic brain injury based on pathological, radiological, and functional measures. Acta Neuropathol Commun. 2021;9:89. doi: 10.1186/s40478-021-01193-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40478-021-01193-8</ArticleId>
            <ArticleId IdType="pmc">PMC8130449</ArticleId>
            <ArticleId IdType="pubmed">34001261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brivio V, Faivre-Sarrailh C, Peles E, Sherman DL, Brophy PJ. Assembly of CNS nodes of ranvier in myelinated nerves is promoted by the axon cytoskeleton. Curr Biol. 2017;27:1068–1073. doi: 10.1016/j.cub.2017.01.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2017.01.025</ArticleId>
            <ArticleId IdType="pmc">PMC5387178</ArticleId>
            <ArticleId IdType="pubmed">28318976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brugarolas P (2021) Investigating the Utility of Demyelination Tracer 18F 3F4AP in Controls and Multiple Sclerosis Subjects</Citation>
        </Reference>
        <Reference>
          <Citation>Calvo M, Richards N, Schmid AB, Barroso A, Zhu L, Ivulic D, Zhu N, Anwandter P, Bhat MA, Court FA, et al.  Altered potassium channel distribution and composition in myelinated axons suppresses hyperexcitability following injury. eLife. 2016 doi: 10.7554/eLife.12661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.12661</ArticleId>
            <ArticleId IdType="pmc">PMC4841771</ArticleId>
            <ArticleId IdType="pubmed">27033551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Capacio BR, Byers CE, Matthews RL, Chang FC. A method for determining 4-aminopyridine in plasma: pharmacokinetics in anaesthetized guinea pigs after intravenous administration. Biomed Chromatogr. 1996;10:111–116. doi: 10.1002/(SICI)1099-0801(199605)10:3&lt;111::AID-BMC569&gt;3.0.CO;2-E.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1099-0801(199605)10:3&lt;111::AID-BMC569&gt;3.0.CO;2-E</ArticleId>
            <ArticleId IdType="pubmed">8792860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen CCH, Popovic MA, Klooster J, Weil MT, Mobius W, Nave KA, Kole MHP. Saltatory conduction along myelinated axons involves a periaxonal nanocircuit. Cell. 2020;180(311–322):e315. doi: 10.1016/j.cell.2019.11.039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2019.11.039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen J (1988) Statistical power analysis for the behavioral sciences. Lawrence Erlbaum Associates, City</Citation>
        </Reference>
        <Reference>
          <Citation>Coman I, Aigrot MS, Seilhean D, Reynolds R, Girault JA, Zalc B, Lubetzki C. Nodal, paranodal and juxtaparanodal axonal proteins during demyelination and remyelination in multiple sclerosis. Brain. 2006;129:3186–3195. doi: 10.1093/brain/awl144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awl144</ArticleId>
            <ArticleId IdType="pubmed">16766541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crawford DK, Mangiardi M, Tiwari-Woodruff SK. Assaying the functional effects of demyelination and remyelination: revisiting field potential recordings. J Neurosci Methods. 2009;182:25–33. doi: 10.1016/j.jneumeth.2009.05.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneumeth.2009.05.013</ArticleId>
            <ArticleId IdType="pubmed">19481113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dams-O'Connor K, Spielman L, Singh A, Gordon WA, Lingsma HF, Maas AI, Manley GT, Mukherjee P, Okonkwo DO, Puccio AM, et al.  The impact of previous traumatic brain injury on health and functioning: a TRACK-TBI study. J Neurotrauma. 2013;30:2014–2020. doi: 10.1089/neu.2013.3049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/neu.2013.3049</ArticleId>
            <ArticleId IdType="pmc">PMC3868372</ArticleId>
            <ArticleId IdType="pubmed">23924069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Giglio L, Cortese F, Pennisi EM. Aminopiridines in the treatment of multiple sclerosis and other neurological disorders. Neurodegener Dis Manag. 2020;10:409–423. doi: 10.2217/nmt-2020-0018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/nmt-2020-0018</ArticleId>
            <ArticleId IdType="pubmed">33054615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Devaux J, Gola M, Jacquet G, Crest M. Effects of K+ channel blockers on developing rat myelinated CNS axons: identification of four types of K+ channels. J Neurophysiol. 2002;87:1376–1385. doi: 10.1152/jn.00646.2001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/jn.00646.2001</ArticleId>
            <ArticleId IdType="pubmed">11877512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dewitt DS, Perez-Polo R, Hulsebosch CE, Dash PK, Robertson CS. Challenges in the development of rodent models of mild traumatic brain injury. J Neurotrauma. 2013;30:688–701. doi: 10.1089/neu.2012.2349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/neu.2012.2349</ArticleId>
            <ArticleId IdType="pubmed">23286417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dietrich M, Hartung HP, Albrecht P. Neuroprotective properties of 4-aminopyridine. Neurol Neuroimmunol Neuroinflamm. 2021 doi: 10.1212/NXI.0000000000000976.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000976</ArticleId>
            <ArticleId IdType="pmc">PMC8529418</ArticleId>
            <ArticleId IdType="pubmed">34667130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dietrich M, Koska V, Hecker C, Gottle P, Hilla AM, Heskamp A, Lepka K, Issberner A, Hallenberger A, Baksmeier C, et al.  Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. Brain. 2020;143:1127–1142. doi: 10.1093/brain/awaa062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awaa062</ArticleId>
            <ArticleId IdType="pubmed">32293668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dileonardi AM, Huh JW, Raghupathi R. Differential effects of FK506 on structural and functional axonal deficits after diffuse brain injury in the immature rat. J Neuropathol Exp Neurol. 2012;71:959–972. doi: 10.1097/NEN.0b013e31826f5876.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/NEN.0b013e31826f5876</ArticleId>
            <ArticleId IdType="pmc">PMC3495060</ArticleId>
            <ArticleId IdType="pubmed">23095847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donders J, Strong CA. Clinical utility of the wechsler adult intelligence scale-fourth edition after traumatic brain injury. Assessment. 2014;22:17–22. doi: 10.1177/1073191114530776.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1073191114530776</ArticleId>
            <ArticleId IdType="pubmed">24752385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duncan GJ, Simkins TJ, Emery B. Neuron-oligodendrocyte interactions in the structure and integrity of axons. Front Cell Dev Biol. 2021;9:653101. doi: 10.3389/fcell.2021.653101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2021.653101</ArticleId>
            <ArticleId IdType="pmc">PMC7982542</ArticleId>
            <ArticleId IdType="pubmed">33763430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duncan ID, Marik RL, Broman AT, Heidari M. Thin myelin sheaths as the hallmark of remyelination persist over time and preserve axon function. Proc Natl Acad Sci U S A. 2017;114:E9685–E9691. doi: 10.1073/pnas.1714183114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1714183114</ArticleId>
            <ArticleId IdType="pmc">PMC5692595</ArticleId>
            <ArticleId IdType="pubmed">29078396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dutta S, Sengupta P. Men and mice: Relating their ages. Life Sci. 2016;152:244–248. doi: 10.1016/j.lfs.2015.10.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2015.10.025</ArticleId>
            <ArticleId IdType="pubmed">26596563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dymowski AR, Ponsford JL, Willmott C. Cognitive training approaches to remediate attention and executive dysfunction after traumatic brain injury: A single-case series. Neuropsychol Rehabil. 2016;26:866–894. doi: 10.1080/09602011.2015.1102746.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09602011.2015.1102746</ArticleId>
            <ArticleId IdType="pubmed">26493353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elfar J (2021) 4-aminopyridine Treatment for Nerve Injury. Identifier NCT03701581. https://ClinicalTrials.gov/show/NCT03701581</Citation>
        </Reference>
        <Reference>
          <Citation>Elfar J (2021) A single dose pharmaco-diagnostic for peripheral nerve continuity after trauma. Identifier NCT04026568. https://ClinicalTrials.gov/show/NCT04026568</Citation>
        </Reference>
        <Reference>
          <Citation>Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, Nerbonne JM, Lichtman JW, Sanes JR. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron. 2000;28:41–51. doi: 10.1016/S0896-6273(00)00084-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0896-6273(00)00084-2</ArticleId>
            <ArticleId IdType="pubmed">11086982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filley CM, Kelly JP. White matter and cognition in traumatic brain injury. J Alzheimers Dis. 2018;65:345–362. doi: 10.3233/JAD-180287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-180287</ArticleId>
            <ArticleId IdType="pubmed">30040722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franssen H. Electrophysiology in demyelinating polyneuropathies. Expert Rev Neurother. 2008;8:417–431. doi: 10.1586/14737175.8.3.417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/14737175.8.3.417</ArticleId>
            <ArticleId IdType="pubmed">18345972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freeman SA, Desmazieres A, Fricker D, Lubetzki C, Sol-Foulon N. Mechanisms of sodium channel clustering and its influence on axonal impulse conduction. Cell Mol Life Sci. 2016;73:723–735. doi: 10.1007/s00018-015-2081-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-015-2081-1</ArticleId>
            <ArticleId IdType="pmc">PMC4735253</ArticleId>
            <ArticleId IdType="pubmed">26514731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodman AD, Stone RT. Enhancing neural transmission in multiple sclerosis (4-aminopyridine therapy) Neurotherapeutics. 2013;10:106–110. doi: 10.1007/s13311-012-0156-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13311-012-0156-3</ArticleId>
            <ArticleId IdType="pmc">PMC3557354</ArticleId>
            <ArticleId IdType="pubmed">23184313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu Y, Jukkola P, Wang Q, Esparza T, Zhao Y, Brody D, Gu C. Polarity of varicosity initiation in central neuron mechanosensation. J Cell Biol. 2017;216:2179–2199. doi: 10.1083/jcb.201606065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.201606065</ArticleId>
            <ArticleId IdType="pmc">PMC5496611</ArticleId>
            <ArticleId IdType="pubmed">28606925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guehl NJ, Neelamegam R, Zhou YP, Moon SH, Dhaynaut M, El Fakhri G, Normandin MD, Brugarolas P. Radiochemical synthesis and evaluation in Non-human primates of 3-[(11)C]methoxy-4-aminopyridine: a novel PET tracer for imaging potassium channels in the CNS. ACS Chem Neurosci. 2021;12:756–765. doi: 10.1021/acschemneuro.0c00791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acschemneuro.0c00791</ArticleId>
            <ArticleId IdType="pmc">PMC8060895</ArticleId>
            <ArticleId IdType="pubmed">33539063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hedrich UBS, Lauxmann S, Wolff M, Synofzik M, Bast T, Binelli A, Serratosa JM, Martinez-Ulloa P, Allen NM, King MD, et al.  4-Aminopyridine is a promising treatment option for patients with gain-of-function KCNA2-encephalopathy. Sci Transl Med. 2021 doi: 10.1126/scitranslmed.aaz4957.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aaz4957</ArticleId>
            <ArticleId IdType="pubmed">34516822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henderson VC, Kimmelman J, Fergusson D, Grimshaw JM, Hackam DG. Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments. PLoS Med. 2013;10:e1001489. doi: 10.1371/journal.pmed.1001489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pmed.1001489</ArticleId>
            <ArticleId IdType="pmc">PMC3720257</ArticleId>
            <ArticleId IdType="pubmed">23935460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsu CG, Talukder MAH, Yue L, Turpin LC, Noble M, Elfar JC. Human equivalent dose of oral 4-aminopyridine differentiates nerve crush injury from transection injury and improves post-injury function in mice. Neural Regen Res. 2020;15:2098–2107. doi: 10.4103/1673-5374.280319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/1673-5374.280319</ArticleId>
            <ArticleId IdType="pmc">PMC7716044</ArticleId>
            <ArticleId IdType="pubmed">32394968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Judge SI, Bever CT., Jr Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006;111:224–259. doi: 10.1016/j.pharmthera.2005.10.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pharmthera.2005.10.006</ArticleId>
            <ArticleId IdType="pubmed">16472864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juengst SB, Nabasny A, Terhorst L. Cohort differences in neurobehavioral symptoms in chronic mild to severe traumatic brain injury. Front Neurol. 2020;10:1342. doi: 10.3389/fneur.2019.01342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2019.01342</ArticleId>
            <ArticleId IdType="pmc">PMC6962245</ArticleId>
            <ArticleId IdType="pubmed">31998213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jukkola P, Gu Y, Lovett-Racke AE, Gu C. Suppression of inflammatory demyelinaton and axon degeneration through inhibiting Kv3 channels. Front Mol Neurosci. 2017;10:344. doi: 10.3389/fnmol.2017.00344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnmol.2017.00344</ArticleId>
            <ArticleId IdType="pmc">PMC5662905</ArticleId>
            <ArticleId IdType="pubmed">29123469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8:e1000412. doi: 10.1371/journal.pbio.1000412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pbio.1000412</ArticleId>
            <ArticleId IdType="pmc">PMC2893951</ArticleId>
            <ArticleId IdType="pubmed">20613859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koliatsos VE, Alexandris AS. Wallerian degeneration as a therapeutic target in traumatic brain injury. Curr Opin Neurol. 2019;32:786–795. doi: 10.1097/WCO.0000000000000763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WCO.0000000000000763</ArticleId>
            <ArticleId IdType="pmc">PMC7147987</ArticleId>
            <ArticleId IdType="pubmed">31633494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lang-Ouellette D, Gruver KM, Smith-Dijak A, Blot FGC, Stewart CA, de Vanssay-de-Blavous P, Li CH, Van Eitrem C, Rosen C, Faust PL, et al.  Purkinje cell axonal swellings enhance action potential fidelity and cerebellar function. Nat Commun. 2021;12:4129. doi: 10.1038/s41467-021-24390-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-021-24390-4</ArticleId>
            <ArticleId IdType="pmc">PMC8257784</ArticleId>
            <ArticleId IdType="pubmed">34226561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levin HS, Temkin NR, Barber J, Nelson LD, Robertson C, Brennan J, Stein MB, Yue JK, Giacino JT, McCrea MA, et al.  Association of sex and age with mild traumatic brain injury-related symptoms: a TRACK-TBI study. JAMA Netw Open. 2021;4:e213046. doi: 10.1001/jamanetworkopen.2021.3046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamanetworkopen.2021.3046</ArticleId>
            <ArticleId IdType="pmc">PMC8025125</ArticleId>
            <ArticleId IdType="pubmed">33822070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Wang X, Li W, Zhang Q, Li Y, Zhang Z, Zhu J, Chen B, Williams PR, Zhang Y, et al.  A sensitized IGF1 treatment restores corticospinal axon-dependent functions. Neuron. 2017;95(817–833):e814. doi: 10.1016/j.neuron.2017.07.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2017.07.037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loring HS, Thompson PR. Emergence of SARM1 as a potential therapeutic target for wallerian-type diseases. Cell Chem Biol. 2020;27:1–13. doi: 10.1016/j.chembiol.2019.11.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2019.11.002</ArticleId>
            <ArticleId IdType="pmc">PMC6980728</ArticleId>
            <ArticleId IdType="pubmed">31761689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marion CM, McDaniel DP, Armstrong RC. Sarm1 deletion reduces axon damage, demyelination, and white matter atrophy after experimental traumatic brain injury. Exp Neurol. 2019;321:113040. doi: 10.1016/j.expneurol.2019.113040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.expneurol.2019.113040</ArticleId>
            <ArticleId IdType="pubmed">31445042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marion CM, Radomski KL, Cramer NP, Galdzicki Z, Armstrong RC. Experimental traumatic brain injury identifies distinct early and late phase axonal conduction deficits of white matter pathophysiology, and reveals intervening recovery. J Neurosci. 2018;38:8723–8736. doi: 10.1523/JNEUROSCI.0819-18.2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.0819-18.2018</ArticleId>
            <ArticleId IdType="pmc">PMC6181309</ArticleId>
            <ArticleId IdType="pubmed">30143572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marmarou CR, Walker SA, Davis CL, Povlishock JT. Quantitative analysis of the relationship between intra- axonal neurofilament compaction and impaired axonal transport following diffuse traumatic brain injury. J Neurotrauma. 2005;22:1066–1080. doi: 10.1089/neu.2005.22.1066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/neu.2005.22.1066</ArticleId>
            <ArticleId IdType="pubmed">16238484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maxwell W, Bartlet E, Morgan H. Wallerian degeneration in the optic nerve stretch-injury model of TBI: a stereological analysis. J Neurotrauma. 2014;32:780–790. doi: 10.1089/neu.2014.3369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/neu.2014.3369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCrea MA, Giacino JT, Barber J, Temkin NR, Nelson LD, Levin HS, Dikmen S, Stein M, Bodien YG, Boase K, et al.  Functional outcomes over the first year after moderate to severe traumatic brain injury in the prospective, longitudinal TRACK-TBI study. JAMA Neurol. 2021;78:982–992. doi: 10.1001/jamaneurol.2021.2043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2021.2043</ArticleId>
            <ArticleId IdType="pmc">PMC8261688</ArticleId>
            <ArticleId IdType="pubmed">34228047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mierzwa AJ, Marion CM, Sullivan GM, McDaniel DP, Armstrong RC. Components of myelin damage and repair in the progression of white matter pathology after mild traumatic brain injury. J Neuropathol Exp Neurol. 2015;74:218–232. doi: 10.1097/NEN.0000000000000165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/NEN.0000000000000165</ArticleId>
            <ArticleId IdType="pmc">PMC4327393</ArticleId>
            <ArticleId IdType="pubmed">25668562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mierzwa AJ, Sullivan GM, Beer LA, Ahn S, Armstrong RC. Comparison of cortical and white matter traumatic brain injury models reveals differential effects in the subventricular zone and divergent sonic hedgehog signaling pathways in neuroblasts and oligodendrocyte progenitors. ASN Neuro. 2014;6:1–16. doi: 10.1177/1759091414551782.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1759091414551782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morehead M, Bartus RT, Dean RL, Miotke JA, Murphy S, Sall J, Goldman H. Histopathologic consequences of moderate concussion in an animal model: correlations with duration of unconsciousness. J Neurotrauma. 1994;11:657–667. doi: 10.1089/neu.1994.11.657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/neu.1994.11.657</ArticleId>
            <ArticleId IdType="pubmed">7723065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nikic I, Merkler D, Sorbara C, Brinkoetter M, Kreutzfeldt M, Bareyre FM, Bruck W, Bishop D, Misgeld T, Kerschensteiner M. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med. 2011;17:495–499. doi: 10.1038/nm.2324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.2324</ArticleId>
            <ArticleId IdType="pubmed">21441916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan S, Chan JR. Regulation and dysregulation of axon infrastructure by myelinating glia. J Cell Biol. 2017;216:3903–3916. doi: 10.1083/jcb.201702150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.201702150</ArticleId>
            <ArticleId IdType="pmc">PMC5716274</ArticleId>
            <ArticleId IdType="pubmed">29114067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pernici CD, Rowe RK, Doughty PT, Madadi M, Lifshitz J, Murray TA. Longitudinal optical imaging technique to visualize progressive axonal damage after brain injury in mice reveals responses to different minocycline treatments. Sci Rep. 2020;10:7815. doi: 10.1038/s41598-020-64783-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-64783-x</ArticleId>
            <ArticleId IdType="pmc">PMC7210987</ArticleId>
            <ArticleId IdType="pubmed">32385407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rasband MN, Trimmer JS, Schwarz TL, Levinson SR, Ellisman MH, Schachner M, Shrager P. Potassium channel distribution, clustering, and function in remyelinating rat axons. J Neurosci. 1998;18:36–47. doi: 10.1523/JNEUROSCI.18-01-00036.1998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.18-01-00036.1998</ArticleId>
            <ArticleId IdType="pmc">PMC6793423</ArticleId>
            <ArticleId IdType="pubmed">9412484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reeves TM, Phillips LL, Povlishock JT. Myelinated and unmyelinated axons of the corpus callosum differ in vulnerability and functional recovery following traumatic brain injury. Exp Neurol. 2005;196:126–137. doi: 10.1016/j.expneurol.2005.07.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.expneurol.2005.07.014</ArticleId>
            <ArticleId IdType="pubmed">16109409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reeves TM, Smith TL, Williamson JC, Phillips LL. Unmyelinated axons show selective rostrocaudal pathology in the corpus callosum after traumatic brain injury. J Neuropathol Exp Neurol. 2012;71:198–210. doi: 10.1097/NEN.0b013e3182482590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/NEN.0b013e3182482590</ArticleId>
            <ArticleId IdType="pmc">PMC3295246</ArticleId>
            <ArticleId IdType="pubmed">22318124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reeves TM, Trimmer PA, Colley BS, Phillips LL. Targeting Kv1.3 channels to reduce white matter pathology after traumatic brain injury. Exp Neurol. 2016;283:188–203. doi: 10.1016/j.expneurol.2016.06.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.expneurol.2016.06.011</ArticleId>
            <ArticleId IdType="pmc">PMC4992637</ArticleId>
            <ArticleId IdType="pubmed">27302680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roseborough A, Hachinski V, Whitehead S. White matter degeneration-A treatable target? JAMA Neurol. 2020;77:793–794. doi: 10.1001/jamaneurol.2020.0814.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2020.0814</ArticleId>
            <ArticleId IdType="pubmed">32338713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simon DJ, Watkins TA. Therapeutic opportunities and pitfalls in the treatment of axon degeneration. Curr Opin Neurol. 2018;31:693–701. doi: 10.1097/WCO.0000000000000621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WCO.0000000000000621</ArticleId>
            <ArticleId IdType="pubmed">30320612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sindhurakar A, Mishra AM, Gupta D, Iaci JF, Parry TJ, Carmel JB. Clinically relevant levels of 4-aminopyridine strengthen physiological responses in intact motor circuits in rats, especially after pyramidal tract injury. Neurorehabil Neural Repair. 2017;31:387–396. doi: 10.1177/1545968316688800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1545968316688800</ArticleId>
            <ArticleId IdType="pmc">PMC5364037</ArticleId>
            <ArticleId IdType="pubmed">28107804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith DH, Hicks R, Povlishock JT. Therapy development for diffuse axonal injury. J Neurotrauma. 2013;30:307–323. doi: 10.1089/neu.2012.2825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/neu.2012.2825</ArticleId>
            <ArticleId IdType="pmc">PMC3627407</ArticleId>
            <ArticleId IdType="pubmed">23252624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith DH, Stewart W. 'Concussion' is not a true diagnosis. Nat Rev Neurol. 2020;16:457–458. doi: 10.1038/s41582-020-0382-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41582-020-0382-y</ArticleId>
            <ArticleId IdType="pmc">PMC7846979</ArticleId>
            <ArticleId IdType="pubmed">32647140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith KJ, Felts PA, John GR. Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain. 2000;123(Pt 1):171–184. doi: 10.1093/brain/123.1.171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/123.1.171</ArticleId>
            <ArticleId IdType="pubmed">10611131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sturrock RR. Changes in neurologia and myelination in the white matter of aging mice. J Gerontol. 1976;31:513–522. doi: 10.1093/geronj/31.5.513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/geronj/31.5.513</ArticleId>
            <ArticleId IdType="pubmed">950445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sturrock RR. Myelination of the mouse corpus callosum. Neuropathol Appl Neurobiol. 1980;6:415–420. doi: 10.1111/j.1365-2990.1980.tb00219.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2990.1980.tb00219.x</ArticleId>
            <ArticleId IdType="pubmed">7453945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sullivan GM, Mierzwa AJ, Kijpaisalratana N, Tang H, Wang Y, Song SK, Selwyn R, Armstrong RC. Oligodendrocyte lineage and subventricular zone response to traumatic axonal injury in the corpus callosum. J Neuropathol Exp Neurol. 2013;72:1106–1125. doi: 10.1097/NEN.0000000000000009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/NEN.0000000000000009</ArticleId>
            <ArticleId IdType="pmc">PMC4130339</ArticleId>
            <ArticleId IdType="pubmed">24226267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor CA, Bell JM, Breiding MJ, Xu L. Traumatic brain injury-related emergency department visits, hospitalizations, and deaths - United States, 2007 and 2013. MMWR Surveill Summ. 2017;66:1–16. doi: 10.15585/mmwr.ss6609a1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15585/mmwr.ss6609a1</ArticleId>
            <ArticleId IdType="pmc">PMC5829835</ArticleId>
            <ArticleId IdType="pubmed">28301451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tseng KC, Li H, Clark A, Sundem L, Zuscik M, Noble M, Elfar J. 4-Aminopyridine promotes functional recovery and remyelination in acute peripheral nerve injury. EMBO Mol Med. 2016;8:1409–1420. doi: 10.15252/emmm.201506035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/emmm.201506035</ArticleId>
            <ArticleId IdType="pmc">PMC5167128</ArticleId>
            <ArticleId IdType="pubmed">27861125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uncini A, Santoro L. The electrophysiology of axonal neuropathies: More than just evidence of axonal loss. Clin Neurophysiol. 2020;131:2367–2374. doi: 10.1016/j.clinph.2020.07.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinph.2020.07.014</ArticleId>
            <ArticleId IdType="pubmed">32828039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Utzschneider DA, Archer DR, Kocsis JD, Waxman SG, Duncan ID. Transplantation of glial cells enhances action potential conduction of amyelinated spinal cord axons in the myelin-deficient rat. Proc Natl Acad Sci U S A. 1994;91:53–57. doi: 10.1073/pnas.91.1.53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.91.1.53</ArticleId>
            <ArticleId IdType="pmc">PMC42884</ArticleId>
            <ArticleId IdType="pubmed">8278406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waxman SG. Determinants of conduction velocity in myelinated nerve fibers. Muscle Nerve. 1980;3:141–150. doi: 10.1002/mus.880030207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.880030207</ArticleId>
            <ArticleId IdType="pubmed">6245357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber MT, Arena JD, Xiao R, Wolf JA, Johnson VE. CLARITY reveals a more protracted temporal course of axon swelling and disconnection than previously described following traumatic brain injury. Brain Pathol. 2019;29:437–450. doi: 10.1111/bpa.12677.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bpa.12677</ArticleId>
            <ArticleId IdType="pmc">PMC6482960</ArticleId>
            <ArticleId IdType="pubmed">30444552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams PR, Marincu BN, Sorbara CD, Mahler CF, Schumacher AM, Griesbeck O, Kerschensteiner M, Misgeld T. A recoverable state of axon injury persists for hours after spinal cord contusion in vivo. Nat Commun. 2014;5:5683. doi: 10.1038/ncomms6683.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms6683</ArticleId>
            <ArticleId IdType="pubmed">25511170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witte ME, Schumacher AM, Mahler CF, Bewersdorf JP, Lehmitz J, Scheiter A, Sanchez P, Williams PR, Griesbeck O, Naumann R, et al.  Calcium influx through plasma-membrane nanoruptures drives axon degeneration in a model of multiple sclerosis. Neuron. 2019;101(615–624):e615. doi: 10.1016/j.neuron.2018.12.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2018.12.023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu ZZ, Li DP, Chen SR, Pan HL. Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit. J Biol Chem. 2009;284:36453–36461. doi: 10.1074/jbc.M109.075523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M109.075523</ArticleId>
            <ArticleId IdType="pmc">PMC2794761</ArticleId>
            <ArticleId IdType="pubmed">19850918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaguchi S, Rogawski MA. Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice. Epilepsy Res. 1992;11:9–16. doi: 10.1016/0920-1211(92)90016-M.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0920-1211(92)90016-M</ArticleId>
            <ArticleId IdType="pubmed">1563341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang YM, Wang W, Fedchyshyn MJ, Zhou Z, Ding J, Wang LY. Enhancing the fidelity of neurotransmission by activity-dependent facilitation of presynaptic potassium currents. Nat Commun. 2014;5:4564. doi: 10.1038/ncomms5564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms5564</ArticleId>
            <ArticleId IdType="pmc">PMC4503407</ArticleId>
            <ArticleId IdType="pubmed">25078759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu F, Shukla DK, Armstrong RC, Marion CM, Radomski KL, Selwyn RG, Dardzinski BJ. Repetitive model of mild traumatic brain injury produces cortical abnormalities detectable by magnetic resonance diffusion imaging (DTI/DKI), histopathology, and behavior. J Neurotrauma. 2017;34:1364–1381. doi: 10.1089/neu.2016.4569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/neu.2016.4569</ArticleId>
            <ArticleId IdType="pmc">PMC5385606</ArticleId>
            <ArticleId IdType="pubmed">27784203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yue JK, Phelps RR, Hemmerle DD, Upadhyayula PS, Winkler EA, Deng H, Chang D, Vassar MJ, Taylor SR, Schnyer DM, et al.  Predictors of six-month inability to return to work in previously employed subjects after mild traumatic brain injury: a TRACK-TBI pilot study. J Concussion. 2021;5:1–11. doi: 10.1177/20597002211007271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/20597002211007271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zang Y, Marder E. Interactions among diameter, myelination, and the Na/K pump affect axonal resilience to high-frequency spiking. Proc Natl Acad Sci U S A. 2021 doi: 10.1073/pnas.2105795118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.2105795118</ArticleId>
            <ArticleId IdType="pmc">PMC8364126</ArticleId>
            <ArticleId IdType="pubmed">34353911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang E, Tian X, Li R, Chen C, Li M, Ma L, Wei R, Zhou Y, Cui Y. Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials. Orphanet J Rare Dis. 2021;16:87. doi: 10.1186/s13023-021-01694-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13023-021-01694-8</ArticleId>
            <ArticleId IdType="pmc">PMC7885571</ArticleId>
            <ArticleId IdType="pubmed">33588903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou YX, Pannu R, Le TQ, Armstrong RC. Fibroblast growth factor 1 (FGFR1) modulation regulates repair capacity of oligodendrocyte progenitor cells following chronic demyelination. Neurobiol Dis. 2012;45:196–205. doi: 10.1016/j.nbd.2011.08.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nbd.2011.08.004</ArticleId>
            <ArticleId IdType="pmc">PMC3225566</ArticleId>
            <ArticleId IdType="pubmed">21854849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zoupi L, Markoullis K, Kleopa KA, Karagogeos D. Alterations of juxtaparanodal domains in two rodent models of CNS demyelination. Glia. 2013;61:1236–1249. doi: 10.1002/glia.22511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/glia.22511</ArticleId>
            <ArticleId IdType="pubmed">23828637</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
